Durata Therapeutics prices IPO at $9, below the range

By
A A A

Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13. Because Durata had planned to offer only 6.3 million shares, the proceeds were just 9% less than expected. Durata Therapeutics plans to list on the NASDAQ under the symbol DRTX. BofA Merrill Lynch and Credit Suisse acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: DRTX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

The Pumpkin Carvers
The Pumpkin Carvers                 

Stocks

Referenced

100%

Most Active by Volume

32,208,647
  • $97.30 ▲ 2.72%
21,575,785
  • $45.30 ▲ 1.05%
14,782,493
  • $70.28 ▲ 1.46%
13,880,513
  • $15.6001 ▲ 0.52%
13,312,657
  • $22.15 ▼ 10.76%
13,177,510
  • $40.84 ▼ 15.18%
11,074,021
  • $28.79 ▲ 0.95%
10,650,650
  • $11.11 ▲ 12.79%
As of 7/23/2014, 10:35 AM